CAMBRIDGE, Mass., March 2, 2011 /PRNewswire/ -- Berg Biosystems, LLC (Berg) and GNS Healthcare, Inc. (GNS), a subsidiary of Via Science, today announced that they have entered into a joint venture named MAP Biosystems, LLC (MAP) to combine their unique capabilities to accelerate advancements in critical biomedical research. MAP will utilize a combination of Berg's novel Interrogative Biology™ drug discovery platform, and GNS's patented supercomputer-driven REFS™ modeling and simulation platform, to unlock the key molecular drivers of complex diseases and drug efficacy and safety. The joint venture will focus on the repositioning of existing drugs for use in new indications with collaborators. Financial terms of the joint venture were not disclosed.
Dr. Niven R. Narain, President & CTO of Berg, said, "MAP represents to biological investigation a new paradigm of physiological understanding based upon a robust network intelligence of disease. The unique combination of unbiased systems biology and artificial-intelligence based systems engineering creates a true data driven approach to therapeutic and diagnostic development."
Narain will be speaking on applications of the Berg discovery platform and the GNS Healthcare platform in La Jolla, CA on March 2nd at the AACR-NCI sponsored conference on Systems Biology: Confronting the Complexity of Cancer. The title of the talk is "Inferring causality to unravel the network intelligence of cancer by employing a novel systems biology drug discovery platform."
The combined platforms will allow for insight into biology drawing from "omic-based", pre-clinical, and clinical data feeds employing computational biology methods to create a differential understanding of disease and health. The collaboration signifies a novel innovative step in medicine that seeks to understand causality and use it as a template for a new generation of drug development.
"MAP has in its arsenal two unparalleled yet complementary technologies – one to generate uniquely deep and broad biological readouts of disease biology and another to readily turn those readouts into knowledge," said Colin C. Hill, CEO and co-founder of GNS Healthcare. "We are looking forward to unraveling hidden mechanisms of efficacy and toxicity of drugs to rapidly address unmet medical needs using these technologies."
About Berg Biosystems, LLC
Berg Biosystems is a Boston, Massachusetts based company that employs a novel approach to systems biology and utilizes systems engineering and bioinformatic modules to cross-validate biological output. The Berg Interrogative Biology™ Drug Discovery Platform allows for rapid and precise identification of therapeutic and biomarker candidates for drug discovery and development. The company uses network biology templates to mine disease pathophysiology.
REFS™ is comprised of integrated machine learning algorithms and software that extract "causal" relationships from complex, multi-dimensional data and enable the simulation of billions of "what if?" hypotheses to explore novel unseen conditions and predictions forward in time. This model-centric discovery and simulation approach represents a paradigm shift in data analysis, leapfrogging existing approaches such as high-dimensional pattern matching. REFS™ is licensed to GNS Healthcare from Via Science.
About GNS Healthcare, Inc.
GNS Healthcare, a subsidiary of Via Science, is a healthcare IT company that applies machine learning and simulation technology to optimize patient treatment in partnership with health insurance companies, pharmacy benefit managers, and pharmaceutical and biotechnology companies. GNS Healthcare is the information guru between drug makers and drug buyers matching drugs to patients to deliver on the promise of "smart" medicine.
For more information, contact Thomas A. Neyarapally, 617-494-0492.
SOURCE GNS Healthcare, Inc.